Research and Markets has announced the addition of the "Iressa - Gefitinib - Oncology Drug Report - 2002-2015 Analysis; 2016-2021 Expectations" report to their offering.

Iressa: on a downward spiral is a comprehensive drug report about the first EGFR tyrosine kinase inhibitor drug in the NSCLC market.

Iressa is the first drug in the EGFR-TKI market to be approved for non-small cell lung cancer. It belongs to AstraZeneca's portfolio and falls in targeted therapy, under the tyrosine kinase inhibitor class of drugs. It is indicated for the treatment locally advanced or meta-static NSCLC."

The report gives basic information about the drug, covering all details from brand name, date of approvals, mechanism of action, molecular structure, route of administration, etc. It has an interesting infographic description of the approval timeline and contains an event tracker, which covers all the major events surrounding the drug, news about Iressa, information on competitor drugs, number of clinical trials (by year and by phase), and so on.

The report gives an analysis of the historical annual sales (from 2006-2015), historical quarterly sales (Q1-2013 to Q3-2016) and sales expectations (from 2016-2021). The analysis broadly indicates that the drug had a strong start but is losing out to competition now and its patent is pending expiry in different geographies starting 2017.

Details of the sales analysis section

Historical annual sales analysis: Historical annual sales have been analysed with the help of graphical representation of sales over 2006-2015. The report has all the data in tabular format as well. We have highlighted key reasons for the sales trend in all the geographies listed.

Historical quarterly sales analysis: Additionally, we have shown sales analysis on quarterly basis for the past 15 quarters from Q1-2013 to Q3-2016. The quarterly data is also in graphical as well as tabular format.

Expected sales analysis: The report has our expectations for Iressa sales over 2016-2021.

Key Topics Covered:

1. Basic Information

2. Approval timeline infographic (2002-2016)

3. Regulatory approval details (US, Europe, Japan and RoW)

4. Historical annual sales analysis

5. Historical quarterly sales analysis (Q1-2013 to Q3-2016)

6. Historical cumulative sales (2002 to Q3-2016)

7. Q3-2016 update

8. Sales expectations (2016E-2021E)

9. List of key approved drugs for NSCLC

10. Event tracker

11. Clinical trials of Iressa (US)

12. DMF filings

13. News around Iressa (including 4 press releases)

Companies Mentioned

  • AstraZeneca
  • BMS
  • Boehringer Ingelheim
  • Celgene
  • Eli Lilly
  • Johnson & Johnson
  • Merck & co.
  • Novartis
  • Pierre Fabre
  • Roche
  • Sanofi

For more information about this report visit http://www.researchandmarkets.com/research/n2tx6l/iressa